03 August 2018
Visiongain’ has launched a new pharma report Global Ortho and Osteobiologics Market 2018-2028: Viscosupplementation Products, Demineralized Bone Matrices, Synthetic Orthobiologics, Bone Morphogenic Protein, Allografts, Plasma-rich Protein, Bone Marrow Aspirate, Osteoarthritis, Spinal Fusion, Fracture, Soft Tissue Injury, Hospitals, Clinics, Research and Academic Institutes
The Ortho and Osteobiologics industry has evolved tremendously in recent years with an array of novel technological development being designated to treat orthopaedic disorders. The regulatory authorities such as the U.S. FDA and EMA are streamlining the regulatory process and approving different advanced devices. There is a huge market potential in the developing countries of Asia-Pacific and LAMEA regions, as the healthcare infrastructure, awareness, and affordability have increased in these regions.
The lead analyst of the report commented “Continuous technological innovations in ortho and osteobiologics industry is set to drive the market at an exponential rate. The emergence of natural biomaterials-based ortho and osteobiologics has revolutionized the ortho and osteobiologics industry as these have several advantages compared to synthetic biomaterials.
Competitive rivalry is intense in the Ortho and Osteobiologics market owing to high number of competitors of nearly equal market size and share. Companies competing in the Ortho and Osteobiologics market are continuously putting efforts to gain market share through novel product launches & product approvals owing to the large scope of product differentiation.”
Leading companies featured in the report include Johnson & Johnson (DePuy Synthes), Medtronic PLC, Colson Associates, Inc. (OsteoMed LLC), Arthrex, Inc, Stryker Corporation, Zimmer Biomet Holdings, Inc. (Zimmer Biomet), Smith & Nephew plc, Orthofix International N.V., Skye Osteobiologics Inc., BioVentus.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.